预约演示
更新于：2024-12-26
Valacyclovir Hydrochloride
盐酸伐昔洛韦
更新于：2024-12-26
概要
基本信息
简介Valacyclovir Hydrochloride是抗病毒药物阿昔洛韦的L-缬氨酸酯盐。它的化学名称是L-缬氨酸-2-[(2-氨基-1,6-二氢-6-氧代-9H-嘌呤-9-基)甲氧基]乙基酯盐酸盐。该药物于1995年6月23日在美国首次获批。VALTREX（Valacyclovir Hydrochloride）是阿昔洛韦的衍生物，其作用机制是DNA聚合酶抑制剂和病毒酶抑制剂。瓦拉西克洛韦氢氯化物适用于治疗生殖器疱疹、带状疱疹、水痘和唇疱疹等病症。此外，该药物也被用于HIV相关用途。 |
药物类型 小分子化药 |
别名 L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine、L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester、Talavir + [37] |
作用机制 DNA polymerase抑制剂(DNA聚合酶抑制剂)、病毒酶抑制剂 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H21ClN6O4 |
InChIKeyZCDDBUOENGJMLV-QRPNPIFTSA-N |
CAS号124832-27-5 |
关联
151
项与 盐酸伐昔洛韦 相关的临床试验IRCT20240803062623N3
Bioequivalence study of two Valacyclovir 1000 mg tablet manufactured by tadbir kala jam company in comparison with Valtrex
CTIS2024-516184-87-00
- HY-029-04
TCTR20240618005
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Valacyclovir 500 mg Film-coated Tablets and Reference Product (Valtrex) in Healthy Thai Volunteers under Fasting Conditions
100 项与 盐酸伐昔洛韦 相关的临床结果
登录后查看更多信息
100 项与 盐酸伐昔洛韦 相关的转化医学
登录后查看更多信息
100 项与 盐酸伐昔洛韦 相关的专利（医药）
登录后查看更多信息
1,597
项与 盐酸伐昔洛韦 相关的文献（医药）2025-01-01BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
Congenital Cytomegalovirus Infection: Update on Screening, Diagnosis and Treatment
Review
作者: Soe, A. ; Heath, P. T. ; Soe, A ; Ville, Y. G. ; Jones, C E ; Khalil, A ; Jones, C. E. ; Ville, Y G ; Khalil, A. ; Heath, P T
Plain language summary:
Cytomegalovirus (CMV) is the most common cause of viral infection in newborn babies, and affects 1 in 200 of all live born infants in high‐income countries; and 1 in 71 in low‐ and middle‐income countries. It is a major cause of hearing loss and brain damage.Women may get CMV infection for the first time during pregnancy (primary infection) or may experience ‘non‐primary’ infection, either by reactivation of previous CMV infection or by a new infection with a different strain of the virus. The most common source of infection to pregnant women is the saliva and urine of young children. Therefore, all pregnant women, especially those in regular contact with young children, should be informed about hygiene‐based measures to reduce the risks, e.g. handwashing.The UK National Screening Committee recommends against universal antenatal or newborn screening for CMV. Testing for CMV is usually offered only to women who develop symptoms of influenza, glandular fever or hepatitis (liver inflammation) during pregnancy, or for those whom a routine ultrasound scan detects fetal anomalies that suggests possible CMV infection.The risk of harm to the fetus is greatest following primary CMV infection of the woman in early pregnancy, and appears to be very low following infection after 12 weeks of pregnancy. Babies with CMV infection at birth may have jaundice, a rash, enlarged liver or spleen, a small brain, or be small for their gestational age. Around 1 in 8 babies born with CMV infection will have clinically detectable signs at birth. The rest will not have any features detectable by clinical examination alone. Therefore, all infants with CMV infection at birth should be followed up at a minimum of up to 2 years of age or later, depending upon the disease status, to check hearing and brain development.Following primary CMV infection in the first 12 weeks of pregnancy, if the woman starts taking the antiviral medicine valaciclovir (valacyclovir) it reduces the risk of the baby becoming infected.Where CMV infection of the fetus in the womb has been confirmed (by amniocentesis, for example), regular ultrasound scans should be offered every 2–3 weeks until birth. Detailed assessment of the fetal brain is an essential part of these scans. Where maternal CMV infection occurs, but fetal infection is not confirmed, repeated ultrasound scans of the fetus should be offered every 2–3 weeks until birth.In infected fetuses, as well as ultrasound scans, an MRI scan of the brain should be offered at 28–32 weeks of gestation (and sometimes repeated 3–4 weeks later) to assess for any signs of harm to the fetal brain.All babies born to women with confirmed or suspected CMV infection should be tested for CMV with a urine or saliva sample within the first 21 days of life.In newborns with symptomatic CMV infection at birth, treatment with antiviral medicine (valganciclovir or ganciclovir) can reduce hearing loss in 5 out of 6 babies, and improve long‐term brain development outcomes in some. There is no licensed vaccine for CMV.
2024-12-31Human Vaccines & Immunotherapeutics
Comprehensive insights into COVID-19 vaccine-associated multiple evanescent white dot syndrome (MEWDS): A systematic analysis of reported cases
Review
作者: Zhao, Mingyi ; Du, Ziye ; Zeng, Yuqin ; Shao, Chuhan
Considering the widespread use of COVID-19 vaccines as a preventive measure against the spread of the virus, it's necessary to direct attention to the adverse effects associated with vaccines in a limited group of populations. Multiple evanescent white dot syndrome (MEWDS) following COVID-19 vaccination is a rare adverse reaction associated with COVID-19 vaccines. In this systematic review, we collected 19 articles with 27 patients up to November 1, 2023, summarizing the basic information, clinical manifestations, examinations, treatments, and recoveries of the 27 patients. The 27 enrolled patients (6 males, 21 females) had a median age of 34.1 years (15-71 years old) and were mainly from 5 regions: Asia (8), the Mediterranean region (8), North America (7), Oceania (3) and Brazil (1). Symptoms occurred post-first dose in 9 patients, post-second dose in 14 (1 with symptoms after both), post-third dose in 1, and both post-second and booster doses in 1, while details on 2 cases were not disclosed. Treatments included tapered oral steroids (6), topical steroids (3), tapered prednisone with antiviral drugs and vitamins (1), and valacyclovir and acetazolamide (1), while 16 received no treatment. All patients experienced symptom improvement, and nearly all patients ultimately recovered. Moreover, we summarized possible hypotheses concerning the mechanism of COVID-19 vaccine-associated MEWDS. The findings provide insights into the clinical aspects of COVID-19 vaccine-associated MEWDS. More attention should be given to patients with vaccine-associated MEWDS, and necessary treatment should be provided to patients experiencing a substantial decline in visual acuity to improve their quality of life.
2024-12-01CURRENT OPINION IN INFECTIOUS DISEASES
Prenatal and postnatal antiviral therapies for the prevention and treatment of congenital cytomegalovirus infections
Review
作者: Chandrasekaran, Preethi ; Lee, Han-Shin ; Sung, Valerie ; Schleiss, Mark R. ; Hui, Lisa
Purpose of review:
Congenital cytomegalovirus infection (cCMV) is the leading infectious cause of sensorineural hearing loss and lifelong neurodevelopmental disabilities. Studies suggest antiviral therapy can prevent fetal infection after maternal primary infection, as well as halt the progression of hearing loss and neurodevelopmental disabilities in newborns with symptomatic cCMV. With growing worldwide momentum on early detection and diagnosis of cCMV, this review describes the exciting recent advances in antiviral therapies in CMV infected pregnant mothers and babies, as well as emerging evidence on anti-CMV vaccines.
Recent findings:
New opportunities for prenatal and neonatal interventions have driven a rising interest in screening and identification of asymptomatic CMV infection. Routine screening of pregnant women to identify primary infection in first trimester is now advocated in Western Europe but has yet to be examined from a public health perspective in other regions. Evidence is emerging for maternal valaciclovir therapy to prevent fetal infection after a maternal primary CMV infection in the first trimester of pregnancy. For those infants who are born with symptomatic cCMV, a 6-month course of valganciclovir, started within the first 4 weeks of life, and possibly up to 13 weeks of life, is the current recommended therapy. However, there is unclear evidence for the benefit of treatment for asymptomatic cCMV and cCMV with isolated hearing loss. Research to identify more effective antivirals and an effective CMV vaccine continues.
Summary:
More research is needed to determine the region-specific applicability of the new European recommendations for routine CMV screening in pregnancy. Areas of uncertainty in postnatal management include timing of initiation, duration of treatment and identifying pediatric subgroups that benefit from modification of the standard treatment recommendations.
100 项与 盐酸伐昔洛韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 巨细胞病毒感染 | 澳大利亚 | 2009-07-09 | |
| 眼带状疱疹 | 澳大利亚 | 2009-07-09 | |
| 疱疹病毒感染 | 阿根廷 | - | 1999-03-07 |
| 单纯疱疹 | 中国 | 1996-01-01 | |
| 水痘 | 美国 | 1995-06-23 | |
| 生殖器疱疹 | 美国 | 1995-06-23 | |
| 唇疱疹 | 美国 | 1995-06-23 | |
| 带状疱疹 | 美国 | 1995-06-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 前列腺癌 | 临床3期 | 美国 | - | 2011-09-01 |
| 前列腺癌 | 临床3期 | 波多黎各 | - | 2011-09-01 |
| HIV感染 | 临床3期 | 美国 | 1999-06-01 | |
| HIV感染 | 临床3期 | 加拿大 | 1999-06-01 | |
| 多形性胶质母细胞瘤 | 临床2期 | 美国 | 2007-03-01 | |
| 脑恶性胶质瘤 | 临床2期 | 美国 | 2007-03-01 | |
| 慢性丙型肝炎 | 临床1期 | 美国 | 2011-11-01 | |
| 胰腺腺癌 | 临床1期 | 美国 | 2008-08-01 | |
| 病毒感染 | 临床前 | 比利时 | 2023-12-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 52 | 繭糧築膚獵憲顧淵齋齋(夢廠壓糧繭夢網鏇鹽齋) = 構顧築衊艱鏇鏇製憲簾 膚蓋簾醖築遞夢餘餘憲 (鏇蓋鬱醖網簾選製醖蓋, 築膚選憲蓋築製艱選鬱 ~ 願顧窪願夢鬱襯構鹹憲) 更多 | - | 2024-04-03 | |||
临床1期 | 58 | Valacyclovir 500 mg | 製鬱壓選膚選願顧醖鑰(廠膚艱顧網鑰遞簾鹹襯) = 積憲夢選網構鹹獵憲蓋 範廠餘願鏇選範鬱簾鏇 (顧繭窪蓋膚襯鬱獵壓醖 ) 更多 | 积极 | 2024-02-26 | ||
Valacyclovir (Control) | 選艱壓襯願獵壓鑰觸簾(壓積鏇窪襯蓋蓋遞積鹽) = 鏇齋餘鏇淵選積簾願衊 艱遞顧憲選構憲鏇齋鬱 (窪齋積鏇願鏇製廠構餘 ) | ||||||
临床2期 | 11 | 願鹹艱鏇艱選鬱鏇製餘(網製鹽膚鬱餘壓淵鹽憲) = 選積構淵蓋獵觸醖蓋糧 廠鏇簾窪襯鏇艱襯鏇醖 (鹽積網選艱構夢壓蓋遞, 蓋醖獵憲顧蓋遞範製糧 ~ 窪遞繭衊齋憲範齋鏇淵) 更多 | - | 2023-09-21 | |||
N/A | - | Acyclovir/Valacyclovir | 蓋鹹夢餘鏇遞範鹹夢遞(鑰衊壓範鏇蓋鬱壓遞壓) = 廠繭夢遞願憲衊獵襯鬱 簾獵齋餘襯壓築鑰願醖 (製憲鏇襯襯繭襯鬱壓壓 ) | 不佳 | 2023-06-14 | ||
蓋鹹夢餘鏇遞範鹹夢遞(鑰衊壓範鏇蓋鬱壓遞壓) = 膚願襯獵遞願淵膚鹽壓 簾獵齋餘襯壓築鑰願醖 (製憲鏇襯襯繭襯鬱壓壓 ) | |||||||
N/A | 84 | 廠願鹹構願遞範構襯遞(壓齋襯膚鹹鹽顧積鏇淵) = 糧構選壓鑰鬱艱網選構 選簾範願鬱鹹蓋壓窪範 (築醖製鏇鹹醖憲選顧淵 ) 更多 | 积极 | 2023-04-01 | |||
Placebo | 齋鏇膚齋獵憲鏇構蓋遞(鬱鹽積構範鹽積構鏇簾) = 構願壓觸鬱壓淵齋衊鹽 製糧餘餘淵鏇鏇鹽襯鏇 (餘願顧網窪願範醖範築 ) | ||||||
N/A | 慢性阻塞性肺疾病 Epstein-Barr virus | 84 | 繭夢鑰鹹製簾範獵鑰鏇(艱繭積選醖網構遞鏇餘) = 築糧糧遞醖蓋憲廠鬱廠 鹽艱膚積憲襯廠觸餘獵 (顧選淵膚鹽繭襯壓窪簾 ) | 积极 | 2022-09-04 | ||
Placebo | 繭夢鑰鹹製簾範獵鑰鏇(艱繭積選醖網構遞鏇餘) = 襯獵遞鏇蓋積繭衊餘獵 鹽艱膚積憲襯廠觸餘獵 (顧選淵膚鹽繭襯壓窪簾 ) | ||||||
临床2期 | 137 | (ValAcyclovir) | 衊築網鑰網製襯鹽餘鏇(製簾壓夢壓鹹醖鏇鹽淵) = 憲醖糧鬱製膚鏇簾繭壓 網構鹹憲積繭糧願鹹艱 (膚鑰簾築襯顧壓壓範觸, 選壓選醖窪鑰築鑰憲簾 ~ 鏇鹽憲憲蓋窪夢夢願網) 更多 | - | 2022-03-16 | ||
(ValGanciclovir) | 衊築網鑰網製襯鹽餘鏇(製簾壓夢壓鹹醖鏇鹽淵) = 艱選積夢製鑰構餘夢積 網構鹹憲積繭糧願鹹艱 (膚鑰簾築襯顧壓壓範觸, 構鑰艱鏇遞願簾壓願顧 ~ 襯夢膚衊淵選鬱艱範獵) 更多 | ||||||
N/A | 37 | 積廠鬱夢構夢憲衊淵鏇(觸膚築積餘願鹽憲壓壓) = 顧簾醖蓋觸遞鏇衊襯鬱 積醖襯獵齋衊範範憲鹹 (憲夢觸網範齋範選夢構, 0.013 ~ 0.67) 更多 | 积极 | 2021-03-01 | |||
積廠鬱夢構夢憲衊淵鏇(觸膚築積餘願鹽憲壓壓) = 窪糧窪壓鏇網鏇簾構範 積醖襯獵齋衊範範憲鹹 (憲夢觸網範齋範選夢構 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用